Quantum Cyber (QUCY) Registration Filing summary

Company overview and business model

• Develops and sells in-vitro diagnostic (IVD) tests for early cancer detection, with flagship product ColoAlert marketed in Europe and next-generation mRNA-based CRC screening in development for US and EU markets.

• Pursues R&D to expand its portfolio, including PancAlert for pancreatic cancer and exclusive licenses for novel mRNA biomarkers.

• Commercial strategy focuses on laboratory partnerships and direct sales to clinical labs, targeting markets with out-of-pocket health expenditures.

• Recently restructured to focus on core products, next-generation test development, and cost reduction measures.

Financial performance and metrics

• 2024 revenues were $893,991, with a net loss of $21,650,663, reflecting ongoing operating losses and early revenue stage.

• Cash as of December 31, 2024, was $6,235,670, with total assets of $13,238,167 and total liabilities of $7,191,624.

• Pro forma net tangible book value after the offering is estimated at $0.99 per share, with dilution to new investors of $1.05 per share.

Use of proceeds and capital allocation

• Net proceeds of approximately $2,565,000 are expected, to be used for the eAArly Detect 2 study, next-generation product development, PancAlert, commercial expansion of ColoAlert, debt repayment, and general corporate purposes.

• Management has broad discretion in the use of proceeds, which may be invested in short-term, investment-grade instruments pending use.